6d ago
TIGERMED - Overseas regulatory announcement - Announcement on changing the use of part of the repurchased shares and canceling and reducing the company's registered capital
HANGZHOU TIGERMED CONSULTING CO., LTD.
Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 3347)
Overseas regulatory announcement
This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.
By order of the board of directors
Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.
Chairman
Ye Xiaoping
Hong Kong, August 28, 2026
As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee directors are Mr. Wu Hao; and the independent non-executive directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Xiao Yaoxi.
Securities code: 300347 Securities abbreviation: Tigermed Announcement Code (2026) No. 046
Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.
Announcement on changing the purpose of part of the repurchased shares and canceling and reducing the company’s registered capital
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and bear joint and several liability for any false records, misleading statements or major omissions in the announcement.
Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") held the second meeting of the sixth board of directors on August 28, 2026, and reviewed and approved the "Proposal on Changing the Use of Partial Repurchases of Shares and Cancel and Reduce the Company's Registered Capital", agreeing that the company will From April 30, 2025 to April 30, 2025, the purpose of the partially repurchased shares totaling 5,883,780 shares was adjusted from "for subsequent implementation of equity incentive plans or employee stock ownership plans" to "cancellation and reduction of registered capital", and cancellation and reduction of the company's registered capital were implemented. The proposal still needs to be submitted to the company’s shareholders’ meeting for review. The details are announced as follows:
Basic information on share repurchase
The company’s fourth meeting of the fifth board of directors held on February 6, 2024 reviewed and approved the “Proposal on the Plan to Repurchase the Company’s Shares.” The seventh meeting of the fifth session of the Board of Directors held on April 12, 2024 reviewed and approved the “Proposal on Adjusting the Plan for Repurchasing the Company’s Shares.” Proposal", and the adjusted "Proposal on the Plan to Repurchase the Company's Shares" was reviewed and approved at the second extraordinary general meeting of shareholders in 2024, the first A-share class meeting in 2024 and the first H-share class meeting in 2024 held on April 30, 2024. According to the share repurchase plan, the company plans to use its own funds or self-raised funds to repurchase some of the company's A shares through centralized bidding transactions or other methods permitted by laws and regulations, for subsequent implementation of equity incentive plans or employee stock ownership plans and cancellation and reduction of registered capital. The number of shares used to implement equity incentive plans or employee stock ownership plans shall not exceed 60% of the total repurchase amount, and the number of shares used to cancel and reduce registered capital shall not be less than 40% of the total repurchase amount. The total amount of funds required to repurchase shares will not be less than RMB 500 million and not exceed RMB 1 million; the repurchase price will not exceed RMB 72 per share. The implementation period of this share repurchase is 12 months from the date of the shareholders' meeting reviewing and approving the share repurchase plan.
As of April 30, 2025, the company's special securities account for share repurchase has repurchased a total of 9,806,300 shares of the company through centralized bidding transactions, accounting for 1.1337% of the company's total share capital, accounting for 1.1337% of Company A's total share capital. The total share capital ratio is 1.3219%, the highest transaction price is 62.00 yuan/share, the lowest transaction price is 48.17 yuan/share, and the total transaction amount is 500,116,483.34 yuan (excluding transaction fees). So far, the company's share repurchase plan has been completed. The actual method, quantity, price, total amount of funds and repurchase period of shares complied with the provisions of relevant laws, regulations, normative documents and repurchase plans. For details, please refer to the "Announcement on the Expiration of the Period for Repurchasing the Company's Shares and Changes in Shares" disclosed by the company on April 30, 2025.
- On May 29, 2025, as confirmed by the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., the company completed the cancellation of 3,922,520 repurchase shares, accounting for 40% of the total number of shares in the company's above-mentioned repurchase plan. The number, completion date and cancellation period of repurchased and canceled shares are all in compliance with relevant laws and regulations. For details, please refer to the "Announcement on the Completion of Cancellation of Partial Repurchased Shares and Changes in Shares" disclosed by the company on May 29, 2025.
As of the announcement date, the company's above-mentioned repurchase plan still has 5,883,780 shares remaining.
- The company changed the purpose of repurchasing shares and canceled them this time
Based on the actual situation of the company, combined with the considerations of safeguarding the interests of investors and enhancing market confidence, the company plans to change the purpose of the remaining shares in the above-mentioned repurchase plan, a total of 5,883,780 shares, from "for subsequent implementation of equity incentive plans or employee stock ownership plans" to "cancellation and reduction of registered capital". After the cancellation is completed, the total number of shares of the company will change from 861,026,050 shares to 855,142,270 shares.
The matter of changing the purpose of part of the repurchased shares and canceling and reducing the company's registered capital still needs to be submitted to the company's shareholders' meeting for review.
- Table of changes in the company’s capital structure after the cancellation of shares
Before this change After this change
This change
Nature of shares Ratio Ratio Quantity (shares) (shares) Quantity (shares)
(%) (%) 1. Circulable shares with sales restrictions 171,426,344 19.91 0 171,426,344 20.05 Executive locked shares 171,426,344 19.91 0 171,426,344 20.05 2. Circulating shares with no sales restrictions
689,599,706 80.09 -5,883,780 683,715,926 79.95 shares
RMB ordinary shares (A
566,474,906 65.79 -5,883,780 560,591,126 65.55 shares)
Overseas listed foreign shares (H
123,124,800 14.30 0 123,124,800 14.40 shares)
Total share capital 861,026,050 100 -5,883,780 855,142,270 100 Note: If there is any discrepancy between the total number and the sum of the sub-items in the above table, it is due to rounding.
The impact of this cancellation of shares on the company
This change of purpose and cancellation of the repurchased shares complies with relevant regulations such as the "Share Repurchase Rules of Listed Companies" and the "Self-Regulatory Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 9 - Repurchase of Shares" and other relevant regulations. It will not have a substantial impact on the company's financial status and operating results, and will not harm the interests of the company and the interests of small and medium-sized investors. After the cancellation of the repurchased shares, the company's equity distribution still meets the conditions for listing and will not change the company's status as a listed company.
- Arrangements for follow-up matters
After the cancellation of the repurchased shares is completed, the company will change the registered capital, amend the relevant provisions of the Articles of Association, handle industrial and commercial change registration and filing and other related matters in accordance with relevant laws and regulations, and perform information disclosure obligations in a timely manner.
Documents available for inspection
Resolution of the second meeting of the company’s sixth board of directors.
Announcement is hereby made.
Board of Directors of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.
August 29, 2026